Thyroid Cancer Drug Pipeline: RET, NTRK — PatSnap Eureka
RET, NTRK & Radioiodine-Refractory Thyroid Cancer: Pipeline Intelligence
From selective RET inhibitors and PROTAC degraders to re-differentiation biologics — explore the full drug discovery landscape for thyroid cancer's most clinically urgent molecular targets, powered by PatSnap Eureka's patent and literature intelligence.
Thyroid Cancer Subtype Distribution
DTC dominates at ~90% of cases; MTC and ATC represent smaller but high-unmet-need segments.
RET: The Dominant Molecular Driver in Thyroid Cancer
Thyroid cancer is the most common endocrine malignancy globally, with differentiated thyroid cancer (DTC) accounting for approximately 90% of all cases. While most DTC patients respond to surgery and radioiodine (RAI), a clinically significant subset develops radioiodine-refractory disease (RAIR-DTC), representing a major unmet need.
The RET proto-oncogene, encoding a receptor tyrosine kinase (RTK), is the dominant molecular driver across thyroid cancer subtypes. RET point mutations account for approximately 65% of medullary thyroid carcinomas (MTC), with germline mutations at codons 609, 611, 618, 620, 634 (MEN2A) and codon M918T (MEN2B) as the most prevalent alterations. In papillary thyroid carcinoma (PTC), somatic RET/PTC fusion proteins occur in approximately 20–30% of adult cases and up to 50% of pediatric PTC cases.
In the NTRK dimension, an NTRK2-TERT gene fusion has been identified as a marker of thyroid tumor aggressiveness and poor prognosis. The co-occurrence of RET/PTC rearrangements with TERT promoter mutations is described as a cooperatively oncogenic "genetic duet," with RET/PTC selectively activating mutant TERT through the MAPK pathway — suggesting co-mutation status may be a predictive biomarker for kinase inhibitor response.
For RAIR-DTC, TGFβ pathway activation has been identified as a mechanism of radioiodine resistance, mediated by loss of thyroid follicular differentiation characteristics. TGFβ pathway inhibition is proposed to restore RAI uptake capacity via re-differentiation. Learn more about patent landscape analysis for oncology targets on the PatSnap platform.
Seven Drug Classes Targeting Thyroid Cancer
From approved selective kinase inhibitors to preclinical PROTAC degraders and CAR-T constructs — the pipeline spans multiple mechanistic approaches across RET, NTRK, and re-differentiation targets.
Selective Small-Molecule RET Inhibitors
BLU-667 (pralsetinib, Blueprint Medicines) at 300–400 mg once daily and LOXO-292 (selpercatinib, Array BioPharma / Eli Lilly) are the benchmark compounds. Selpercatinib received EMA approval per a 2021 paper from the University of Campania. Next-generation HM06/TAS0953 (Taiho Pharmaceutical) targets acquired resistance including V804M, V804L, and Y806C mutations, with coverage for CNS/leptomeningeal metastases.
EMA-approved selpercatinibMulti-Kinase Inhibitors (MKIs)
Lenvatinib (Eisai) and structurally related quinoline carboxamide analogs target RET kinase across MEN2A, MEN2B, familial MTC, sporadic MTC, and PTC. Eisai biomarker patents describe thyroglobulin levels and mutation status as predictors of lenvatinib response in DTC. Blueprint Medicines notes MKI treatment is associated with significant toxicity and response durations typically less than one year.
Lenvatinib companion diagnosticsRET-Targeted Combination Regimens
Blueprint Medicines holds patents covering BLU-667 + mTORC1 inhibitors (everolimus or AZD8055) for thyroid cancer, addressing mTOR-mediated bypass resistance. A separate filing covers RET inhibitor + osimertinib (EGFR inhibitor) for EGFR-mutant, RET co-activated cancers. The Southern University of Science and Technology proposes RET + MEK co-inhibition for PTC patients with RET/PTC + TERT promoter co-mutations.
mTORC1 bypass resistance rationalePROTAC-Based RET Degraders
C4 Therapeutics (JP, 2023) describes proteolysis-targeting chimeras (PROTACs) designed to induce selective degradation of wild-type or mutant RET protein. PROTACs work through protein ubiquitination and proteasomal degradation — distinct from competitive kinase inhibition — potentially addressing resistance mutations at the ATP-binding site. Evidence is exclusively patent-based at this stage.
Resistance-overcoming mechanismAnti-RET Monoclonal Antibodies
Regeneron Pharmaceuticals holds patents (JP, CN, 2022) covering fully human monoclonal antibodies against RET receptor tyrosine kinase. These antibodies block GDNF/GFRα complex interaction with RET, preventing ligand-dependent receptor dimerization and downstream signaling, with applicability to PTC and MTC thyroid tumors noted in the filings.
Ligand-dependent dimerization blockadeRAI Re-Differentiation: TGFβ & Thyromimetics
West China Hospital (CN, 2020) proposes TGFβ pathway inhibitors to restore NIS-mediated iodine uptake in RAIR-DTC by reversing dedifferentiation. The University of Vermont (WO/CA, 2021) patents cover thyroid hormone receptor beta-1 (TRβ) agonists (thyromimetics) in combination with primary cancer therapeutics to induce cancer cell differentiation in radioiodine-refractory and undifferentiated thyroid cancer settings.
NIS restoration strategyRET Mutation Prevalence & Pipeline Modality Landscape
Key quantitative signals from patent and literature analysis via PatSnap Eureka — all data points sourced directly from retrieved records.
RET Oncogenic Alteration Prevalence by Thyroid Cancer Subtype
RET mutations dominate in MTC (65%); RET/PTC fusions occur in 20–30% of adult PTC and up to 50% of pediatric PTC cases.
Thyroid Cancer Pipeline: Modalities by Development Stage
Selective RET inhibitors and MKIs are at clinical/approved stage; PROTAC degraders, antibodies, and re-differentiation biologics remain preclinical per retrieved records.
Who Owns the Thyroid Cancer Drug Pipeline IP?
Patent ownership signals competitive positioning, freedom-to-operate risk, and next-generation development priorities across the RET, NTRK, and RAIR-DTC space.
Blueprint Medicines Corporation
Dominates with more than 15 active, pending, or expired patent records across US, EP, JP, IL, SG, CA, AU, WO, MX, and MY jurisdictions. Core coverage: selective RET inhibitor Compound 1 (pralsetinib/BLU-667 successor), therapeutic use claims for RET-altered thyroid and lung cancer, RET + mTORC1 combinations, and EGFR co-inhibition strategies.
Array BioPharma (Pfizer) & Eisai
Array BioPharma holds patents in TW, RS, and JP jurisdictions covering pyrazolo[1,5-a]pyridine, pyrazolo[4,3-c]pyridine, pyrazolo[3,4-d]pyrimidine, and pyrrolo[2,3-d]pyrimidine scaffolds — structural coverage underlying selpercatinib (LOXO-292). Eisai holds multiple patents (EP, US, AU, JP) for lenvatinib and quinoline carboxamide MKIs, plus companion biomarker patents for lenvatinib response prediction in DTC.
Taiho Pharmaceutical & Chugai Seiyaku
Taiho holds pending patents (CN, JP, 2023–2024) for HM06/TAS0953, a next-generation RET inhibitor targeting acquired resistance mutations (V804M/L, Y806C) with CNS coverage — signaling an emerging resistance-overcoming inhibitor class. Chugai Seiyaku holds active patents (ES, SG, IL, MX) covering tetracyclic RET inhibitor compounds with distinct scaffolds from Blueprint and Array compounds.
Regeneron, C4 Therapeutics & Boehringer Ingelheim
Regeneron holds active patents (JP, CN) for fully human anti-RET monoclonal antibodies blocking GDNF/GFRα complex interaction. C4 Therapeutics holds a JP 2023 patent for PROTAC-based RET degraders. Boehringer Ingelheim holds WO and EP patents covering nintedanib and the CCDC6-RET fusion biomarker strategy for thyroid and lung cancer patient selection.
Beyond Monotherapy: The Next Wave of Thyroid Cancer IP
RET + mTORC1 Co-inhibition is the most IP-protected combination strategy in this dataset. Blueprint Medicines WO and US patents (2018–2021) cover BLU-667 + everolimus or BLU-667 + AZD8055, addressing mTOR-mediated bypass resistance in thyroid cancer. The mechanistic rationale is that mTORC1 pathway activation represents a bypass resistance mechanism to selective RET inhibition.
RET + MEK Co-inhibition for RET/PTC + TERT-mutant PTC: The Southern University of Science and Technology pending patent (CN, 2024) provides a pharmacogenomic rationale for targeting the RET + MEK axis specifically in PTC patients carrying both RET/PTC rearrangements and TERT promoter mutations, suggesting biomarker-stratified combination trial designs may be warranted.
PROTAC-Based RET Degradation: C4 Therapeutics' PROTAC platform (JP, 2023) signals a move toward protein degradation as a strategy to overcome resistance to RET kinase inhibitors. Since PROTACs work through protein ubiquitination and proteasomal degradation, they may address resistance mutations at the ATP-binding site — a key limitation of current approved agents. According to NCI, targeted protein degradation is an active area of oncology drug discovery.
TGFβ Pathway Inhibition + RAI Re-differentiation: The West China Hospital patent (CN, 2020) proposes TGFβ inhibitors as combination partners for RAI in RAIR-DTC, restoring iodine avidity rather than directly killing cancer cells. The life sciences IP intelligence available through PatSnap can help map the full TGFβ inhibitor landscape for thyroid cancer re-differentiation strategies. The European Bioinformatics Institute maintains curated target data relevant to TGFβ pathway drug discovery.
Immune Checkpoint Inhibition in ATC: A Mayo Clinic case report (2021) describes disease control with combined high-dose radiation and pembrolizumab in ATC with PD-L1 expression at 95% by IHC — providing a translational signal for immunotherapy in PD-L1-high ATC. Jiangsu Hengrui Medicine (CN, 2023) holds a tyrosine kinase inhibitor + anti-PD-1 antibody combination patent for thyroid cancer, signaling growing interest in immuno-oncology approaches.
Track Resistance Mutation Patents in Real Time
Monitor V804M, V804L, Y806C and emerging acquired-resistance RET mutation filings as they publish.
From Patent Filings to Clinical Evidence
The dataset spans approved agents with Phase I/II data through to preclinical-stage PROTAC and CAR-T constructs. Here are the key translational signals retrieved.
Selpercatinib (LOXO-292): Phase I/II Data & EMA Approval
A 2021 academic paper from the University of Campania "Luigi Vanvitelli" describes selpercatinib's EMA approval and Phase I/II clinical data. The Phase I study enrolled patients with RET-altered cancers; the Phase II study stratified cohorts by tumor type, RET alteration, and prior therapies. Primary endpoint was objective response rate (ORR) by independent review; secondary endpoints included duration of response, progression-free survival, and safety.
ORR primary endpointPralsetinib (BLU-667): Dose Range Optimization Signals
Blueprint Medicines patent language consistently references 300–400 mg once-daily dosing of Compound 1 (pralsetinib/BLU-667), with the US 2024 filing expanding the dose range to 60–400 mg — suggesting dose optimization iterations typical of late-stage clinical development. Blueprint's portfolio spans US, EP, JP, IL, SG, CA, AU, WO, MX, and MY jurisdictions.
60–400 mg dose range (2024 filing)HM06/TAS0953: Acquired-Resistance Clinical Evaluation
The HM06/TAS0953 patent (Taiho Pharmaceutical, 2023–2024) references patients "previously receiving another RET selective inhibitor" with "developed resistance," suggesting this compound is in clinical evaluation for acquired-resistance settings. The filing explicitly addresses patients who have progressed on, or developed resistance to, prior selective RET inhibitors or MKIs, with coverage for CNS/leptomeningeal metastases.
Post-selpercatinib/pralsetinib indicationATC + Pembrolizumab: PD-L1 95% Disease Control Case
A 2021 academic paper from the Mayo Clinic Division of Medical Oncology describes a case of anaplastic thyroid cancer (ATC) — arising from an underlying PTC previously treated with surgery and RAI — achieving disease control with combined high-dose radiation and pembrolizumab. PD-L1 expression was measured at 95% by IHC, providing a translational signal for immunotherapy in ATC as a PD-L1-high subset.
PD-L1 95% by IHCNo IND-enabling study, phase III, or regulatory submission data were identified in retrieved results for the TGFβ pathway inhibitor approach, thyromimetics, PROTAC RET degraders, anti-RET antibodies, or TSHR CAR-T. This report is derived from a limited set of patent and literature records and represents a snapshot of innovation signals within this dataset only — it should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape. For comprehensive pipeline surveillance, use PatSnap Eureka or the PatSnap platform.
Thyroid Cancer Drug Pipeline — key questions answered
The RET proto-oncogene is the dominant molecular driver across thyroid cancer subtypes. RET point mutations account for approximately 65% of medullary thyroid carcinomas (MTC), while somatic RET/PTC fusions occur in approximately 20–30% of adult papillary thyroid carcinoma (PTC) and up to 50% of pediatric PTC cases. NTRK rearrangements, including NTRK2-TERT gene fusions, are also identified as markers of aggressiveness and poor prognosis.
Differentiated thyroid cancer (DTC) accounts for approximately 90% of all thyroid cancer cases. While the majority of DTC patients respond to surgery and radioiodine (RAI), a clinically significant subset develops radioiodine-refractory disease (RAIR-DTC), representing a major unmet need. TGFβ pathway activation has been identified as a mechanism of radioiodine resistance, mediated by loss of thyroid follicular differentiation characteristics.
BLU-667 (pralsetinib, Blueprint Medicines Corporation) and LOXO-292 (selpercatinib, Array BioPharma / Eli Lilly) are selective, ATP-competitive small-molecule inhibitors targeting the RET kinase domain. Pralsetinib is administered at 300–400 mg once daily. Selpercatinib received EMA approval and is described in a 2021 academic paper from the University of Campania in a clinical context including Phase I/II data.
Blueprint Medicines Corporation dominates this dataset with more than 15 active, pending, or expired patent records spanning US, EP, JP, IL, SG, CA, AU, WO, MX, and MY jurisdictions. Their core asset cluster covers selective RET inhibitor Compound 1 (pralsetinib/BLU-667 successor), therapeutic use claims for RET-altered thyroid and lung cancer, combination with mTORC1 inhibitors, and EGFR co-inhibition.
Blueprint Medicines Corporation holds patents covering combinations of RET inhibitors (BLU-667) with mTORC1 inhibitors (everolimus or AZD8055) for cancers mediated by aberrant RET activity, with thyroid cancer as a preferred indication. A separate Blueprint filing covers RET inhibitor combined with EGFR inhibitor osimertinib. The Southern University of Science and Technology pending patent provides a pharmacogenomic rationale for targeting the RET + MEK axis specifically in PTC patients carrying both RET/PTC rearrangements and TERT promoter mutations.
C4 Therapeutics holds a patent (JP, 2023) describing proteolysis-targeting chimeras (PROTACs) designed to induce selective degradation of wild-type or mutant RET protein. Since PROTACs work through mechanisms distinct from competitive kinase inhibition (protein ubiquitination and proteasomal degradation), they may address resistance mutations at the ATP-binding site. This represents an emerging modality beyond kinase inhibition, potentially addressing resistance mutations.
Still have questions? Let PatSnap Eureka search the RET and NTRK patent literature for you.
Ask Eureka AI Your Pipeline QuestionAccelerate Your Thyroid Cancer Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map RET, NTRK, and RAIR-DTC patent landscapes, monitor competitor filings, and identify white-space opportunities.
References
- RET inhibitor for use in treating cancer having a RET alteration — Blueprint Medicines Corporation, 2024, US [Patent]
- RET inhibitor for use in treating cancer having a RET alteration — Blueprint Medicines Corporation, 2023, EP [Patent]
- RET inhibitor for use in treating cancer having a RET alteration — Blueprint Medicines Corporation, 2021, US [Patent]
- RET inhibitor for use in treating cancer having a RET alteration — Blueprint Medicines Corporation, 2019, WO [Patent]
- Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors — Array BioPharma Inc., 2020, RS [Patent]
- Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors — Array BioPharma Inc., 2025, JP [Patent]
- Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA — University of Campania "Luigi Vanvitelli," 2021 [Paper]
- Antitumor agent for thyroid cancer — Eisai R&D Management Co., Ltd., 2009, EP [Patent]
- Biomarkers for predicting and assessing the responsiveness of lenvatinib compounds to thyroid and kidney cancer subjects — Eisai R&D Management Co., Ltd., 2016, JP [Patent]
- Method using a RET fusion gene as a biomarker to select NSCLC and thyroid cancer patients for cancer treatment — Boehringer Ingelheim International GmbH, 2017, WO [Patent]
- Combinations of RET inhibitors and mTORC1 inhibitors — Blueprint Medicines Corporation, 2018, WO [Patent]
- Combinations of RET Inhibitors and mTORC1 Inhibitors — Blueprint Medicines Corporation, 2021, US [Patent]
- Compounds for targeted degradation of RET — C4 Therapeutics, Inc., 2023, JP [Patent]
- Human antibodies that bind RET and methods of use thereof — Regeneron Pharmaceuticals, Inc., 2022, JP [Patent]
- TGFβ pathway inhibitor use in preparing drugs to improve radioiodine treatment sensitivity in thyroid cancer — West China Hospital, Sichuan University, 2020, CN [Patent]
- Use of thyromimetics for the treatment of cancer — The University of Vermont, 2021, WO [Patent]
- A replication-deficient recombinant lentiviral CAR-T transgenic vector targeting TSHR — Wuhan BoRuida Biotechnology Co., Ltd., 2021, CN [Patent]
- World Health Organization — Thyroid Cancer Classification and Global Incidence Data
- National Cancer Institute — Thyroid Cancer Treatment (PDQ)
- European Bioinformatics Institute — RET Gene Target Data & Pathway Resources
- NCBI Gene — RET proto-oncogene (Gene ID: 5594)
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.